title: Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?
abstract: BACKGROUND
  Cancer patients undergo routine computed-tomography (CT) scans and, therefore, iodinated contrast media (ICM) administration. It is not known whether a time-dependent correlation exists between chemotherapy administration, contrast enhanced CT and onset of acute ICM-related adverse reactions (ARs).
  
  
  METHODS
  All consecutive contrast-enhanced CTs performed from 1 January 2010 to 31 December 2012 within 30 days of the last chemotherapy administration were retrospectively reviewed. Episodes of acute ICM-related ARs were reported to the pharmacovigilance officer. We analyzed time to CT evaluation calculated as the time elapsed from the date of the CT performed to the date of the last chemotherapy administration. Patients were classified into 4 groups based on the antineoplastic treatment: platinum-based, taxane-based, platinum plus taxane and other group.
  
  
  RESULTS
  Out of 10,472 contrast-enhanced CTs performed, 3,945 carried out on 1,878 patients were considered for the study. Forty acute ICM-related ARs (1.01%; 95% CI, 0.70-1.33) were reported. No differences were seen among immediate (within 10 days of the last chemotherapy administration), early (11-20 days) and delayed (21-30 days) CTs. Median time to CT in patients who experienced an acute ICM-related AR by treatment group was not statistically different: 20 days (range 6-30), 17 days (range 5-22), 13 days (range 8-17), 13 days (range (2-29) for the platinum, taxane, platinum plus taxane and other group, respectively (P =0.251).
  
  
  CONCLUSIONS
  Our results did not reveal any correlation between time to CT and risk of acute ICM-related ARs in cancer patients.
authors.affiliation: Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, via Piero Maroncelli 40, Meldola 47014, Italy. alberto.farolfi@irst.emr.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Farolfi
authors.forename: Elisa
authors.initials: E
authors.lastname: Carretta
authors.forename: Corradina Della
authors.initials: CD
authors.lastname: Luna
authors.forename: Angela
authors.initials: A
authors.lastname: Ragazzini
authors.forename: Nicola
authors.initials: N
authors.lastname: Gentili
authors.forename: Carla
authors.initials: C
authors.lastname: Casadei
authors.forename: Domenico
authors.initials: D
authors.lastname: Barone
authors.forename: Martina
authors.initials: M
authors.lastname: Minguzzi
authors.forename: Dino
authors.initials: D
authors.lastname: Amadori
authors.forename: Oriana
authors.initials: O
authors.lastname: Nanni
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Gavelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D015994:Incidence; D007457:Iodine Radioisotopes; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D016017:Odds Ratio; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000009:adverse effects; D055815:Young Adult
chemical_list: D003287:Contrast Media; D007457:Iodine Radioisotopes